Gómez MO, Romero MKA, Lizardi CJ

Language: Spanish
References: 19
Page: 17-22
PDF size: 49.32 Kb.

ABSTRACT

Multiple sclerosis is a demyelinating disorder, characterized by inflammation and selective destruction of central nervous system myelin. In western societies, is the second cause of neurologic disability in early to middle adulthood. The course of multiple sclerosis can be relapsing remitting or progressive and its manifestations vary from a benign illness to a rapidly evolving and incapacitating isease requiring profound life-style adjustments. This review focuses on the current knowledge of the epidemiology, risk factors, classification and treatment of the inflammatory and neurodegenerative elements of multiple sclerosis.

REFERENCES

1. Kasper et al. Harrison´s Principles of Internal Medicine. Meningitis, Encephalitis, Brain Abscess and Empyema. 16th edition. 2005: 2461-2471.

2. Compston A, Ebers G, Lassmann H et al. McAlpine’s Multiple Sclerosis. 3rd Ed. London: Churchill Livingstone. 1998.

3. Noseworthy JH, Lucchinetti C, Rodríguez M et al. Multiple Sclerosis. N Engl J Med 2000; 343: 938-952.

4. Ascheiro A, Zahng SM, Hernan MA et al. Hepatitis B vaccination and the risk of Multiple sclerosis. N Engl J Med 2001; 344: 327-332.

5. Confravreux C, Suissa S, Saddier P et al. Vaccinations and the risk of relapsing Multiple Sclerosis. Vaccines in Multiple Sclerosis study group. N Engl J Med 2001; 344: 319-326.

6. Schrivjer HM, Crusins JB, Uliderhaag BM et al. Association of Leukin 1β1-interleukin, receptor antagonists genes with disease severity in MS. Neurol 1999; 52: 595-599.

7. Sadovnick AD, Armstrong H, Rice GP et al. A population based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33: 281-285.

8. Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with multiple sclerosis. Neurol 2000; 54: 256.

9. Lublin FD. The diagnosis of Multiple Sclerosis. Curr Opin Neurol 2002; 15: 253-256.

10. 10.McDonald WI, Compston A, Edan G et al. Recommended diagnosis criteria for Multiple Sclerosis: Guideliness from the International Panel diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.

11. 11.Arnold DL, Matthews PM. MRI in the diagnosis and management of Multiple Sclerosis. Neurol 2002; 58: S23-31.

12. 12.Berger T, Rubner P, Schautzer F et al. Antimyelin antibodies as a predictor of clinical definite multiple sclerosis after a first demyelinating. N Engl J Med 2003; 349: 139-145.

13. 13.Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence based review): Report of the equality standards subcommittee of the American Acad Neurol 2000; 54: 1720-1725.

14. 14.Frohman E, Rackle M, Raine C. Multiple Sclerosis – The plaque and its Pathogenesis. N Engl J Med 2006; 354: 942-955.

15. 15.Thompson AJ, Montalban X, Barkhof F, Brochet B et al. Diagnostic Criteria for primary progressive Multiple Esclerosis: a position paper. Ann Neurol 2000; 47: 831-835.

16. 16.Beck RW, Cleary PA, Anderson MM et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-588.

17. 17.Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroid for acute of optic neuritis of the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-1769.

18. 18.Weinshenker BG, O’Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.

19. 19.Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon Beta 1st therapy initiate during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 2000; 343: 898-904.